Abstract 10: Antenatal Low Dose Magnesium Sulphate for Fetal Neuroprotection in Preterm Birth versus Control: A Comparative Prospective Cohort Study

Abstract Background: Preterm infants are at great risk of neurological impairments. Premature births bring with itself a series of complication turning future neonatal course into a turbulent journey, however its long-term impact on mental development of the baby is further devastating. This study aimed to evaluate what is the difference in short-and long-term neonatal outcome comparing magnesium sulphate in small dose (4-gram) versus controls. Methods: Prospective cohort study was conducted in the Department of Obstetrics and Gynaecology over a period of 4 years. Group A comprised of the study group (intravenous 4-gram magnesium sulphate was given over 20 min). Group B consisted of control group who did not receive magnesium sulphate. Results: The study population comprised of 116 pregnant women who intravenous bolus of 4-gram MgSO4 while the control group comprised of 95 pregnant women who did not receive MgSO4. Fewer neonates in the MgSO4 group required intubation at birth (32% vs. 52%) or chest compression (4% vs. 6%), however the difference was not statistically significantly (p=0.175 and p=0.329). Neonatal brain ultrasound done in first month showed a significant reduction intraventricular haemorrhage of severe grade 3–4 IVH in the MgSO4 group (p = 0.016). MgSO4 administration was associated with a decrease in neonatal mortality before discharge (p = 0.039). Follow up at 3 years, showed a significant reduction in delayed milestones, visual impairment, Bayley score < 85 (p = 0.015). Conclusion: MgSO4 treatment antenatally was associated with lower risk of neonatal mortality. 23.2%, p